$23.01
0.00%
Nasdaq, Thu, Feb 27 2025
ISIN
US41358P1066
Symbol
HARP
Sector
Industry

Harpoon Therapeutics, Inc. Stock price

$23.01
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.07 0.31% 1Y
-17.99 43.88% 3Y
-118.89 83.78% 5Y
-111.99 82.96% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.00%
ISIN
US41358P1066
Symbol
HARP
Sector
Industry

Key metrics

Market capitalization $492.35m
Enterprise Value $475.24m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.73
P/S ratio (TTM) P/S ratio 13.19
Revenue growth (TTM) Revenue growth 16.14%
Revenue (TTM) Revenue $37.34m
EBIT (operating result TTM) EBIT $-37.39m
Free Cash Flow (TTM) Free Cash Flow $-69.50m
Cash position $31.61m
EPS (TTM) EPS $-8.71
P/E forward negative
P/S forward 2.25
EV/Sales forward 1.84
Short interest 3.24%
Show more

Is Harpoon Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Harpoon Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:

Hold
100%

Financial data from Harpoon Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
37 37
16% 16%
100%
- Direct Costs 2.82 2.82
1% 1%
8%
35 35
18% 18%
92%
- Selling and Administrative Expenses 12 12
26% 26%
33%
- Research and Development Expense 57 57
30% 30%
152%
-35 -35
49% 49%
-93%
- Depreciation and Amortization 2.82 2.82
1% 1%
8%
EBIT (Operating Income) EBIT -37 -37
47% 47%
-100%
Net Profit -31 -31
57% 57%
-82%

In millions USD.

Don't miss a Thing! We will send you all news about Harpoon Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harpoon Therapeutics, Inc. Stock News

Neutral
Investors Business Daily
3 months ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.

Company Profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dalton Smart
Founded 2015
Website www.harpoontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today